Abstract:Background Prostate‐specific membrane antigen (PSMA) Positron emission tomography/computed tomography (PET/CT) has become a crucial imaging modality for the staging of patients with prostate cancer. The purpose of this study is to retrospectively determine the frequency, anatomical distribution, and clinical‐pathologic correlates of extra‐nodal and extra‐osseous metastatic prostate cancer detected on PSMA PET/CT. Methods All available 650 PSMA PET/CT performed in patients with biopsy‐proved prostate cancer in our institution between September 2021 and December 2023 were reviewed for the presence of extra‐nodal and extra‐osseous metastatic disease (M1C disease). Thirty‐four patients with M1C disease were identified. Results The most frequent sites of visceral/soft tissue metastases were the lungs (58.8%), liver (23.5%) and adrenal glands (20.6%). 75% of patients with lung metastases detected on PSMA PET/CT had concurrent intrathoracic lymph node involvement. A higher frequency of patients with M1C disease (55.9%) had a high Gleason score. The median prostate‐specific antigen (PSA) level at the time of the PSMA scan was 20.16 ng/mL. There was a statistically significant association between PSA level and osseous disease (p = 0.004), as well as PSA level and nodal disease (p = 0.008). While a large number of patients had concurrent osseous and nodal disease (82.4% and 79.4%, respectively), no visceral/soft tissue sites demonstrated a significant association with the presence of osseous or nodal involvement. Conclusions Given the increasing utilization of PSMA PET/CT, increased knowledge of the location and pattern of distribution of visceral/soft tissue metastatic sites is crucial not only for staging but also to better understand patterns of therapeutic response. We identified the lungs, liver and adrenal glands as the most common visceral/soft tissue metastatic sites from prostate cancer. We found that higher PSA levels at the time of PSMA PET/CT imaging were positively associated with concurrent osseous and nodal involvement.

De Novo Metastatic Prostate Cancer Presenting With Atypical Lower-Limb Skeletal Metastases Detected on 68Ga-PSMA PET/CT

Metastatic Prostate Carcinoma to the Ankle Seen on Bone Scintigraphy and Extended Field-of-View PSMA PET/CT

Unusual Presentation of Solitary Penile Metastasis of Prostate Cancer on 68Ga-PSMA PET/CT

Prostate-Specific Membrane Antigen–Avid Neurofibroma Mimicking Cutaneous Metastasis in Metastatic Castration-Resistant Prostate Cancer on 18F-PSMA-1007 PET/CT

Incidental Finding of Spindle Cell Sarcoma on 68Ga-PSMA-11 PET/CT

Unusual Perineal Metastasis in a Case of Prostate Cancer on 68Ga-PSMA-11 PET/CT

68 Ga-PSMA-11 PET/CT and 64 CuCl 2 PET/CT Help in Identifying Rare Metastatic Site of Penile Shaft in a Patient of Carcinoma Prostate

Extrapleural solitary fibrous tumor evidenced by 68Ga-prostate-specific membrane antigen positron emission tomography/computed tomography study in the staging of a high-risk prostate cancer patient

Unsuspected Isolated Peritoneal Metastasis of Prostate Cancer Detected with Digital F-18 PSMA PET/CT Scan

Primary Adenosquamous Carcinoma of the Prostate With Multiple Heterogenic Metastases Demonstrated on 68Ga-PSMA and 18F-FDG PET/CT Imaging

A single‐center retrospective review of metastatic prostate cancer on PSMA position emission tomography/computed tomography: Beyond lymph nodes and bones

Cutaneous, Subcutaneous, and Bilateral Adrenal Gland Metastases in Progressive Prostate Carcinoma: Theranostic Potential of 68Ga-PSMA-11 PET/CT Imaging and 177Lu-PSMA-617 Therapy

Unusual Prostate-Specific Membrane Antigen (PSMA) Splenic Uptake in a Patient With Prostate Cancer

Enchondroma on Bone Scan and PSMA PET/CT in a Patient With Prostate cancer

A Retrospective Multicenter Analysis of the Incidence of Bone-Only Disease at PSMA PET/CT in Castration Resistant Prostate Cancer Patients

Detection of benign granular cell tumor of the breast via 18F-PSMA-PET/CT in a patient with very high-risk prostate cancer: A case report

Metastatic Prostate Adenocarcinoma with Neuroendocrine Differentiation on 18F-FDG PET/CT, 68Ga-Psma PET/CT and 68Ga-Dota TATE PET/CT with Injected Ultra-Low-activity

Renal Pelvis Metastasis from Prostatic Adenocarcinoma Missed by PSMA PET: A Case Report.

Case Report: 18F-PSMA-1007 PET/CT Avid Solitary Penile Metastasis of Castration-Resistant Prostate Cancer With a PSA of 0.072 ng/ml

Multiple osteolytic bone and lung metastases from prostate cancer including small cell carcinoma with marked increases in CEA and Pro-GRP

Bone and Lymph Node Flare to Androgen Deprivation Therapy in Metastatic Hormone-Sensitive Prostate Cancer on 18F–Prostate-Specific Membrane Antigen PET/CT With Decreasing Prostate-Specific Antigen of 0.7 ng/mL